Stock listing
OTC:BNXTF BioNxt Solutions Inc Stock
US listing (OTC) of BioNxt Solutions Inc · home listing CSE:BNXT
Follow BioNxt Solutions Inc into a list and get an email when it puts out news.
Share price · OTC:BNXTF
$0.205 USD 0.000 (0.0%)
Close on Nov 6, 2026
- Day range
- $0.205 – $0.205 USDNov 6, 2026
- Market cap
- $27.94M USDAt the close on Nov 6, 2026 · price × 136.1M shares outstanding
- 52-week range
- $0.100 – $0.569 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $534 USDMedian day 130 shares · 30 days with no trades · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BNXT · Home | $0.26 CAD | -0.01 (-3.7%) | 11,000 | $0.26 | $0.26 | $0.26 | $0.27 | Close on Nov 6, 2026 |
| Xetra:BXT | €0.176 EUR | +0.012 (+7.3%) | 10,505 | €0.167 | €0.188 | €0.167 | €0.164 | Close on Nov 6, 2026 |
| OTC:BNXTF | $0.205 USD | 0.000 (0.0%) | — | $0.205 | $0.205 | $0.205 | $0.205 | Close on Nov 6, 2026 |
| Frankfurt:BXT | €0.155 EUR | -0.007 (-4.3%) | 1,500 | €0.158 | €0.158 | €0.147 | €0.162 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · OTC:BNXTF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.205 | 0.000 | 0.0% | $0.205 | $0.205 | $0.205 | 0 | |
| $0.205 | 0.000 | 0.0% | $0.205 | $0.205 | $0.205 | 0 | |
| $0.205 | 0.000 | 0.0% | $0.205 | $0.205 | $0.205 | 0 | |
| $0.205 | +0.004 | +2.0% | $0.205 | $0.205 | $0.205 | 200 | |
| $0.201 | -0.005 | -2.2% | $0.155 | $0.201 | $0.155 | 240 | |
| $0.206 | 0.000 | 0.0% | $0.206 | $0.206 | $0.206 | 0 | |
| $0.206 | -0.004 | -2.0% | $0.206 | $0.206 | $0.206 | 2,000 | |
| $0.210 | +0.005 | +2.6% | $0.205 | $0.210 | $0.205 | 500 | |
| $0.205 | -0.005 | -2.6% | $0.205 | $0.205 | $0.205 | 2,500 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.210 | 0 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.210 | 0 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.210 | 0 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.210 | 0 | |
| $0.210 | +0.005 | +2.6% | $0.213 | $0.213 | $0.210 | 49,856 | |
| $0.205 | -0.017 | -7.8% | $0.205 | $0.205 | $0.205 | 5,000 | |
| $0.222 | +0.004 | +1.9% | $0.227 | $0.227 | $0.222 | 10,400 | |
| $0.218 | 0.000 | 0.0% | $0.218 | $0.218 | $0.218 | 0 | |
| $0.218 | 0.000 | 0.0% | $0.218 | $0.218 | $0.218 | 0 | |
| $0.218 | +0.005 | +2.5% | $0.100 | $0.218 | $0.100 | 52,000 | |
| $0.213 | -0.049 | -18.8% | $0.213 | $0.213 | $0.213 | 5,000 | |
| $0.262 | +0.049 | +23.0% | $0.262 | $0.262 | $0.262 | 500 | |
| $0.213 | -0.017 | -7.6% | $0.213 | $0.213 | $0.213 | 2,000 | |
| $0.230 | -0.045 | -16.3% | $0.230 | $0.230 | $0.230 | 1,050 | |
| $0.275 | 0.000 | 0.0% | $0.275 | $0.275 | $0.275 | 0 | |
| $0.275 | +0.005 | +1.8% | $0.275 | $0.275 | $0.275 | 1,300 | |
| $0.270 | 0.000 | 0.0% | $0.270 | $0.270 | $0.270 | 0 | |
| $0.270 | +0.004 | +1.4% | $0.270 | $0.270 | $0.270 | 135 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | 0.000 | 0.0% | $0.266 | $0.266 | $0.266 | 0 | |
| $0.266 | +0.023 | +9.5% | $0.266 | $0.266 | $0.266 | 500 | |
| $0.243 | -0.018 | -6.7% | $0.214 | $0.243 | $0.214 | 1,578 | |
| $0.261 | +0.001 | +0.2% | $0.261 | $0.261 | $0.261 | 100 | |
| $0.260 | 0.000 | 0.0% | $0.260 | $0.260 | $0.260 | 0 | |
| $0.260 | 0.000 | 0.0% | $0.260 | $0.260 | $0.260 | 250 | |
| $0.260 | 0.000 | 0.0% | $0.260 | $0.260 | $0.260 | 0 | |
| $0.260 | -0.002 | -0.8% | $0.270 | $0.270 | $0.260 | 400 | |
| $0.262 | 0.000 | 0.0% | $0.262 | $0.262 | $0.262 | 0 | |
| $0.262 | +0.015 | +5.9% | $0.262 | $0.262 | $0.262 | 198 | |
| $0.248 | -0.005 | -2.1% | $0.241 | $0.248 | $0.241 | 3,368 | |
| $0.253 | 0.000 | 0.0% | $0.227 | $0.253 | $0.227 | 1,000 | |
| $0.253 | +0.030 | +13.3% | $0.253 | $0.253 | $0.253 | 2,030 | |
| $0.223 | 0.000 | 0.0% | $0.223 | $0.223 | $0.223 | 0 | |
| $0.223 | 0.000 | 0.0% | $0.223 | $0.223 | $0.223 | 0 | |
| $0.223 | -0.053 | -19.3% | $0.223 | $0.223 | $0.223 | 125 | |
| $0.276 | 0.000 | 0.0% | $0.276 | $0.276 | $0.276 | 0 | |
| $0.276 | 0.000 | 0.0% | $0.276 | $0.276 | $0.276 | 0 | |
| $0.276 | +0.049 | +21.8% | $0.276 | $0.276 | $0.276 | 2,000 | |
| $0.227 | 0.000 | 0.0% | $0.227 | $0.227 | $0.227 | 0 | |
| $0.227 | +0.001 | +0.4% | $0.227 | $0.227 | $0.227 | 1,000 | |
| $0.226 | -0.002 | -0.7% | $0.226 | $0.226 | $0.226 | 306 | |
| $0.228 | +0.010 | +4.6% | $0.260 | $0.260 | $0.228 | 13,363 | |
| $0.218 | 0.000 | 0.0% | $0.218 | $0.218 | $0.218 | 0 | |
| $0.218 | 0.000 | 0.0% | $0.218 | $0.218 | $0.218 | 0 | |
| $0.218 | -0.009 | -3.8% | $0.214 | $0.242 | $0.214 | 320 | |
| $0.226 | 0.000 | 0.0% | $0.226 | $0.226 | $0.226 | 0 | |
| $0.226 | -0.009 | -3.7% | $0.240 | $0.240 | $0.226 | 318 | |
| $0.235 | +0.007 | +2.9% | $0.235 | $0.235 | $0.235 | 132 | |
| $0.228 | -0.006 | -2.5% | $0.220 | $0.228 | $0.220 | 2,907 | |
| $0.234 | +0.006 | +2.4% | $0.234 | $0.234 | $0.234 | 200 | |
| $0.229 | +0.009 | +4.1% | $0.229 | $0.229 | $0.229 | 100 | |
| $0.220 | -0.014 | -6.0% | $0.220 | $0.220 | $0.220 | 130 | |
| $0.234 | +0.021 | +10.0% | $0.213 | $0.234 | $0.213 | 300 |
- Ticker
- OTC:BNXTF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 19, 2026
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Oct 19, 2026
Closed $0.205 (-7.8%) on Oct 19, 2026
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Sep 8, 2026
Closed $0.248 (-2.1%) on Sep 8, 2026
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Aug 21, 2026
Closed $0.226 (-0.7%) on Aug 24, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Aug 4, 2026
Closed $0.215 (0.0%) on Aug 4, 2026
BioNxt Solutions Announces Option Grants
Jul 31, 2026
Closed $0.215 (0.0%) on Aug 3, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
Jul 6, 2026
Closed $0.213 (-7.6%) on Jul 6, 2026
BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 23, 2026
Closed $0.242 (0.0%) on Jun 24, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Jun 15, 2026
Closed $0.25 (-1.5%) on Jun 15, 2026
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 12, 2026
Closed $0.25 (-1.5%) on Jun 15, 2026
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
Jun 10, 2026
Closed $0.266 (-4.4%) on Jun 11, 2026
Financings
Private placement of units
Jun 23, 2026 · US$1.41M
Closed: C$2M raised · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of units
Jun 12, 2026 · US$1.43M
Announced: up to C$2M · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of convertible debenture units
Aug 8, 2025
Closed: C$1.25M raised · C$0.6 a unit · 1 warrant at C$0.75 for 24 months · Canaccord Genuity Corp. · free to trade Dec 9, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, and general working capital
Announced Jul 11, 2025 · Tranche closed Jul 25, 2025 · Closed Aug 8, 2025
Convertible debenture units
Mar 14, 2025
Closed: C$2.5M raised · C$0.5 a unit · 1 warrant at C$0.6 for 24 months · Canaccord Genuity Corp. · free to trade Jul 15, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, debt repayment, and general working capital
Decks
Investor Presentation (September 2026)
Investor deck · 27 slides · September 2026
Investor Presentation (November 2024)
Investor deck · 23 slides · November 2024
XPhyto Therapeutics — Investor Presentation (June 2021)
Investor deck · 16 slides · June 2021
BioNxt Solutions Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 66 in all · newest Oct 19, 2026 · oldest 2024
- Decks
- 3 decks · latest September 2026
Where BioNxt Solutions Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BNXT · Home listing | CSE | Canada | CAD |
| Xetra:BXT | Xetra | Germany | EUR |
| gettex:BXT | gettex | Germany | EUR |
| LS Exchange:A3D1K3 | LS Exchange | Germany | EUR |
| Tradegate:BXT | Tradegate | Germany | EUR |
| Lang & Schwarz:A3D1K3 | Lang & Schwarz | Germany | EUR |
| Cboe Canada:BNXT | Cboe Canada | Canada | CAD |
| OTC:BNXTF · This page | OTC | United States | USD |
| Frankfurt:BXT | Frankfurt | Germany | EUR |
| Dusseldorf:BXT | Dusseldorf | Germany | EUR |
| Hamburg:BXT | Hamburg | Germany | EUR |
| Munich:BXT | Munich | Germany | EUR |
| Stuttgart:BXT | Stuttgart | Germany | EUR |
| Hanover:BXT | Hanover | Germany | EUR |
Log in to ask 6ix AI your own questions about BioNxt Solutions Inc.